ListarArtículos (Medicina) por materia "Inflammatory bowel disease"
Mostrando ítems 1-9 de 9
-
Artículo
Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
(Sage Publishing, 2022)Background: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in ...
-
Artículo
How is inflammatory bowel disease managed in Spanish gastroenterology departments? The results of the GESTIONA-EII survey
(Aran Ediciones S.A., 2016)Introduction: Not all national health centers include special ized units or clinicians devoted to inflammatory bowel ...
-
Artículo
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
(Frontiers Media S.A., 2022)Background: Previous studies comparing immigrant ethnic groups and native patients with IBD have yielded clinical and ...
-
Artículo
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
(MDPI, 2022)We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for ...
-
Artículo
Native Chilean Berries Preservation and In Vitro Studies of a Polyphenol Highly Antioxidant Extract from Maqui as a Potential Agent against Inflammatory Diseases
(MDPI, 2021-05)The best conservation method for native Chilean berries has been investigated in combination with an implemented large-scale ...
-
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
(Lippincott Williams & Wilkins, 2017)Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory ...
-
Artículo
The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab
(Aran Ediciones S.A., 2023)Background: the success of strategies with earlier anti-TNF drugs for the treatment of inflammatory bowel disease (IBD) ...
-
Artículo
Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: results from the VERNE study
(Elsevier, 2022)Background Anti-TNFα represent one of the main treatment approaches for the management of inflammatory bowel diseases ...
-
Artículo
Ustekinumab in Crohn’s disease: real-world outcomes and predictors of response
(Aran Ediciones S.A., 2022)Background: ustekinumab is a monoclonal antibody that inhibits interleukins IL-12 and IL-23, and is approved for the ...